Syngene (SYNGENE) | Stock Overview & Key Data
Syngene Performance Comparison
Stock Range
Today's Range
Low: ₹613.35
High: ₹625.75
on September 30, 2025
52 Week Range
Low: ₹599.55
High: ₹960.60
on May 9, 2025
on December 2, 2024
All-Time High: ₹960.60 on December 2, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR250.3B
EPS
12.72
P/E Ratio (TTM)
48.97
Forward P/E
36.96
P/B Ratio
5.30
PEG Ratio
3.43
Div. Yield
0.39%
ROE
10.50%
Beta
0.019
Debt to Equity
12.23
Financial Highlights
Profitability
Gross Margin
75.12%
Operating Margin
11.44%
Profit Margin
13.61%
Returns and Earnings
Return on Assets (TTM)
7.30%
Return on Equity (TTM)
10.50%
EBITDA
INR11.3B
Net Income (TTM)
INR5.1B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR92.86
Quarterly Revenue Growth (YoY)
10.70%
Quarterly Earnings Growth (YoY)
14.50%
Dividend Information
Last 12-Month Dividend
₹2.50
Current Dividend Yield
0.39%
3-Year Average Dividend Yield
0.14%
3-Year Average Annual Dividend
₹1.25
3-Year Total Dividends
₹3.75
Ex-Dividend Date
June 27, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Syngene SYNGENE | 250.35B Large-cap | -3.23% | -1.94% | -2.51% | -13.27% | -29.16% | -28.05% | 10.41% | 11.27% |
| Dr. Lal PathLabs LALPATHLAB | 265.33B Large-cap | -4.11% | -3.16% | 14.23% | 32.06% | 3.79% | -9.34% | 29.77% | 54.23% |
| Sai Life Sciences SAILIFE | 180.28B Mid-cap | -0.54% | 4.98% | 13.77% | 17.23% | 17.04% | 26.08% | 26.08% | 26.08% |
| Metropolis METROPOLIS | 106.47B Mid-cap | -1.97% | -5.00% | 19.34% | 33.83% | -0.75% | -8.67% | 32.94% | 3.77% |
| Vijaya Diagnostic VIJAYA | 104.75B Mid-cap | -4.61% | -3.82% | 2.36% | 3.12% | -5.56% | 1.47% | 117.04% | 60.08% |
| Thyrocare THYROCARE | 64.96B Mid-cap | -4.77% | -10.95% | 17.89% | 59.18% | 24.62% | 42.83% | 65.94% | 7.48% |
Ownership & Short Interest
Insider Ownership
53.10%
Institutional Ownership
32.18%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
601K
Average 90-Day Volume
602K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is SYNGENE's 52-week high and low?
- In the last 52 weeks, Syngene reached a high of ₹960.60 (on December 2, 2024) and a low of ₹599.55 (on May 9, 2025).
- What is the market cap and P/E ratio for SYNGENE?
- Curious about Syngene's size and valuation? Its market capitalization stands at 250.35B. When it comes to valuation, the P/E ratio (trailing twelve months) is 48.97, and the forward P/E (looking ahead) is 36.96.
- Does SYNGENE pay dividends? If so, what's the yield?
- Yes, Syngene is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.39%, and the company has paid an average of ₹1.25 per share annually over the past 3 years.
- Who are Syngene's main competitors or similar companies to consider before investing?
When looking at Syngene, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Dr. Lal PathLabs
LALPATHLAB265.33B Healthcare Diagnostics & Research -9.34% 29.77% Sai Life Sciences
SAILIFE180.28B Healthcare Diagnostics & Research 26.08% 26.08% Metropolis
METROPOLIS106.47B Healthcare Diagnostics & Research -8.67% 32.94% Vijaya Diagnostic
VIJAYA104.75B Healthcare Diagnostics & Research 1.47% 117.04% Thyrocare
THYROCARE64.96B Healthcare Diagnostics & Research 42.83% 65.94% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Syngene International Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Syngene's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 10.50%, the Debt to Equity ratio from the most recent quarter is 12.23, and its Gross Profit Margin stands at 75.12%.
- What is the recent revenue and earnings growth for SYNGENE?
- Looking at Syngene's growth, its revenue over the trailing twelve months (TTM) was INR37B. Compared to the same quarter last year (YoY), quarterly revenue grew by 10.70%, and quarterly earnings saw a YoY growth of 14.50%.
- How much of SYNGENE stock is held by insiders and institutions?
- Wondering who owns Syngene stock? Company insiders (like executives and directors) hold about 53.10% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 32.18%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.